	US 12,391,750 B2
	Anti-C1S antibodies and methods of use thereof
Sandip Panicker, South San Francisco, CA (US); Graham Parry, South San Francisco, CA (US); and Nancy E. Stagliano, South San Francisco, CA (US)
Assigned to Bioverativ USA Inc., Waltham, MA (US)
Filed by Bioverativ USA Inc., Waltham, MA (US)
Filed on Jul. 7, 2023, as Appl. No. 18/349,027.
Application 18/349,027 is a continuation of application No. 16/340,991, abandoned, previously published as PCT/US2017/056349, filed on Oct. 12, 2017.
Claims priority of provisional application 62/407,390, filed on Oct. 12, 2016.
Prior Publication US 2024/0076363 A1, Mar. 7, 2024
Int. Cl. A61K 39/00 (2006.01); A61K 39/395 (2006.01); C07K 16/18 (2006.01); A61K 38/00 (2006.01); A61K 45/06 (2006.01)

CPC C07K 16/18 (2013.01) [A61K 38/00 (2013.01); A61K 45/06 (2013.01); C07K 2317/24 (2013.01); C07K 2317/52 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)]

16 Claims

1. A method of inhibiting a complement pathway in a subject having chronic inflammatory demyelinating polyneuropathy (CIDP), comprising administering to the subject a pharmaceutically effective amount of an antibody that specifically binds activated C1s and comprises:

a light chain variable (VL) region comprising the amino acid sequence of SEQ ID NO: 22;

a light chain constant region;

a heavy chain variable (VH) region comprising the amino acid sequence of SEQ ID NO: 14; and

a heavy chain IgG4 constant region comprising a proline (pro), a glutamic acid (glu), a leucine (leu), and a serine (ser) substitution at amino acid residues 108, 115, 308, and 314, respectively, relative to the IgG4 constant region sequence of SEQ ID NO: 52.